Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - gemcitabine hydrochloride, quantity: 228 mg (equivalent: gemcitabine, qty 200 mg) - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; sodium acetate trihydrate - gemcitabine ebewe is indicated for treatment of patients with: . - locally advanced or metastatic non-small cell lung cancer (nsclc) . - locally advanced or metastatic adenocarcinoma of the pancreas. - fluorouracil refractory pancreatic cancer. - (alone or in combination with cisplatin) bladder cancer. . - (in combination with paclitaxel) unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. . - (in combination with carboplatin) recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - gemcitabine hydrochloride, quantity: 227.71 mg (equivalent: gemcitabine, qty 200 mg) - injection, powder for - excipient ingredients: sodium acetate trihydrate; hydrochloric acid; sodium hydroxide; mannitol - gemcitabine drla is indicated for treatment of patients with locally advanced or metastatic non-small cell lung cancer. ,gemcitabine drla is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. ,gemcitabine drla is also indicated for patients with 5-fu refractory pancreatic cancer. ,gemcitabine, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. ,gemcitabine drla in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ,gemcitabine drla in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum?based therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - gemcitabine hydrochloride, quantity: 1138.52 mg (equivalent: gemcitabine, qty 1000 mg) - injection, powder for - excipient ingredients: hydrochloric acid; sodium hydroxide; sodium acetate trihydrate; mannitol - gemcitabine drla is indicated for treatment of patients with locally advanced or metastatic non-small cell lung cancer. ,gemcitabine drla is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine drla is also indicated for patients with 5-fu refractory pancreatic cancer. ,gemcitabine alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. ,gemcitabine drla in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ,gemcitabine drla in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum?based therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - gemcitabine hydrochloride, quantity: 2277 mg (equivalent: gemcitabine, qty 2000 mg) - injection, powder for - excipient ingredients: hydrochloric acid; mannitol; sodium hydroxide; sodium acetate trihydrate - gemcitabine drla is indicated for treatment of patients with locally advanced or metastatic non-small cell lung cancer. ,gemcitabine drla is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. ,gemcitabine drla is also indicated for patients with 5-fu refractory pancreatic cancer. ,gemcitabine, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. ,gemcitabine drla in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ,gemcitabine drla in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum?based therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - gemcitabine hydrochloride, quantity: 2.28 g (equivalent: gemcitabine, qty 2 g) - injection, powder for - excipient ingredients: sodium hydroxide; sodium acetate; hydrochloric acid; mannitol - gemcitabine injection is indicated for treatment of patients with locally advanced or metastatic non- small cell lung cancer.,gemcitabine injection is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine an for injection is also indicated for patients with 5-fu refractory pancreatic cancer.,gemcitabine injection, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer.,gemcitabine injection, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.,gemcitabine injection, in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum? based therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - gemcitabine hydrochloride, quantity: 1138.526 mg (equivalent: gemcitabine, qty 1000 mg) - injection, powder for - excipient ingredients: sodium hydroxide; mannitol; sodium acetate; hydrochloric acid - gemcitabine an for injection is indicated for treatment of patients with locally advanced or metastatic non-small cell lung cancer. gemcitabine an for injection is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine an for injection is also indicated for patients with 5-fu refractory pancreatic cancer. gemcitabine an for injection, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. gemcitabine an for injection, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. gemcitabine an for injection, in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed >6 months following platinum-based therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - gemcitabine hydrochloride, quantity: 227.705 mg (equivalent: gemcitabine, qty 200 mg) - injection, powder for - excipient ingredients: sodium hydroxide; hydrochloric acid; sodium acetate; mannitol - gemcitabine an for injection is indicated for treatment of patients with locally advanced or metastatic non-small cell lung cancer. gemcitabine an for injection is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine an for injection is also indicated for patients with 5-fu refractory pancreatic cancer. gemcitabine an for injection, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. gemcitabine an for injection, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. gemcitabine an for injection, in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed >6 months following platinum-based therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 45.54 mg/ml - injection - excipient ingredients: mannitol; sodium acetate trihydrate; water for injections; hydrochloric acid; sodium hydroxide - gemcitabine for injection, usp (gemcitabine hydrochloride) is indicated for the: treatment of patients with locally advanced (nonresectable stage ii or stage iii) or metastatic (stage iv) adenocarcinoma of the pancreas to achieve a clinical benefit response (a composite measure of clinical imporvement). treatment of patients with locally advanced or metastatic non-small lung cancer (nsclc) as either a single agent or in combination with cisplatin. treatment of patients with stage iv (locally advanced or metastatic) transitional cell carcinoma (tcc) of the bladder in combination with cisplatin. treatment, in combination with paclitaxel, of patients with inresectable, locally recurrent or metastatic breast cancer, who have good performance status and have relapsed following adjuvant anthracycline-based chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 45.54 mg/ml - injection - excipient ingredients: mannitol; sodium acetate trihydrate; water for injections; hydrochloric acid; sodium hydroxide - gemcitabine for injection, usp (gemcitabine hydrochloride) is indicated for the: treatment of patients with locally advanced (nonresectable stage ii or stage iii) or metastatic (stage iv) adenocarcinoma of the pancreas to achieve a clinical benefit response (a composite measure of clinical imporvement). treatment of patients with locally advanced or metastatic non-small lung cancer (nsclc) as either a single agent or in combination with cisplatin. treatment of patients with stage iv (locally advanced or metastatic) transitional cell carcinoma (tcc) of the bladder in combination with cisplatin. treatment, in combination with paclitaxel, of patients with inresectable, locally recurrent or metastatic breast cancer, who have good performance status and have relapsed following adjuvant anthracycline-based chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 45.54 mg/ml - injection - excipient ingredients: mannitol; sodium acetate trihydrate; water for injections; hydrochloric acid; sodium hydroxide - gemcitabine for injection, usp (gemcitabine hydrochloride) is indicated for the: treatment of patients with locally advanced (nonresectable stage ii or stage iii) or metastatic (stage iv) adenocarcinoma of the pancreas to achieve a clinical benefit response (a composite measure of clinical imporvement). treatment of patients with locally advanced or metastatic non-small lung cancer (nsclc) as either a single agent or in combination with cisplatin. treatment of patients with stage iv (locally advanced or metastatic) transitional cell carcinoma (tcc) of the bladder in combination with cisplatin. treatment, in combination with paclitaxel, of patients with inresectable, locally recurrent or metastatic breast cancer, who have good performance status and have relapsed following adjuvant anthracycline-based chemotherapy.